Invega Approval History

  • FDA approved: Yes (First approved December 19th, 2006)
  • Brand name: Invega
  • Generic name: paliperidone
  • Company: Janssen, L.P.
  • Treatment for: Schizophrenia

Invega (paliperidone) is a once-daily oral atypical antipsychotic indicated for the acute and maintenance treatment of schizophrenia, and the acute treatment of schizoaffective disorder. Invega Sustenna is an extended-release injectable formulation of paliperidone administered once-monthly for the acute and maintenance treatment of schizophrenia.

FDA Approval History for Invega

DateArticle
Apr 11, 2011Approval Invega Approved as Treatment for Schizophrenia in Adolescents
Aug  6, 2009Approval Invega Approved as the First and Only Treatment for Schizoaffective Disorder
Aug  3, 2009Approval FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia
Feb  6, 2009Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and Invega
Aug 27, 2008FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
Oct 29, 2007Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal Technology
Apr 27, 2007Approval FDA Approves Invega for Long-Term Maintenance Treatment of Schizophrenia
Dec 21, 2006Approval Invega Approved By FDA as New Treatment for Schizophrenia
Nov 10, 2006Janssen, L.P. Selects Invega (paliperidone) Extended Release Tablets as Brand Name for Its Investigational Atypical Antipsychotic
Sep 29, 2006FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
Nov 30, 2005New Drug Application Submitted for Paliperidone - a Potential New Treatment for Schizophrenia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)